Issue 12, 2019

Construction and optimization of microbial cell factories for sustainable production of bioactive dammarenediol-II glucosides

Abstract

Ginsenosides, the predominant bioactive components of Panax species, are biosynthesized by glycosylation at C3–OH and/or C20–OH of protopanaxadiol (PPD), and C6–OH and/or C20–OH of protopanaxatriol (PPT). Dammarenediol-II (DM), the direct precursor of PPD, has two hydroxyls at C3 and C20 positions, but DM glucosides have scarcely been identified from Panax species. Herein, we used two crude recombinant UDP-glycosyltransferases (UGTs), PgUGT74AE2 and UGTPg1 from Panax ginseng, to catalyze the glycosylation of DM with UDP-glucose (UDPG) as the sugar donor to produce DM glucosides 3-O-β-D-glucopyranosyl-dammar-24-ene-3β,20S-diol (3β-O-Glc-DM) and 20-O-β-D-glucopyranosyl-dammar-24-ene-3β,20S-diol (20S-O-Glc-DM), respectively. The in vitro and in vivo assays demonstrated that both 3β-O-Glc-DM and 20S-O-Glc-DM exhibited higher anti-colon cancer activities than natural ginsenosides. In order to produce DM glucosides in an economical, efficient and convenient way, we refactored the complete biosynthetic pathways of 3β-O-Glc-DM and 20S-O-Glc-DM by introducing the codon-optimized genes encoding DM synthase (DS) together with PgUGT74AE2 or UGTPg1 into Saccharomyces cerevisiae, respectively. Furthermore, multistep metabolic engineering strategies were applied, including optimization of chassis cell, multi-copy integration of heterologous genes via the CRISPR/Cas9 system, increase of precursor supply by overexpressing rate-limiting enzymes, down-regulation of the competitive pathway to redirect the metabolic flux towards the target products, and overexpression of the transcriptional activator. Finally, the titers of 2.4 g L−1 3β-O-Glc-DM and 5.6 g L−1 20S-O-Glc-DM were achieved through fed-batch fermentation in a 3 L bioreactor. This is the first study to demonstrate the anti-colon cancer activities of DM glucosides and to achieve the de novo biosynthesis of DM glucosides with high titers in microbial cell factories. This study has established a green and sustainable approach for the industrial production of DM glucosides, which provides promising candidates for new drug research and development.

Graphical abstract: Construction and optimization of microbial cell factories for sustainable production of bioactive dammarenediol-II glucosides

Supplementary files

Article information

Article type
Paper
Submitted
29 Dec 2018
Accepted
08 Mar 2019
First published
24 Apr 2019
This article is Open Access
Creative Commons BY-NC license

Green Chem., 2019,21, 3286-3299

Construction and optimization of microbial cell factories for sustainable production of bioactive dammarenediol-II glucosides

Z. Hu, A. Gu, L. Liang, Y. Li, T. Gong, J. Chen, T. Chen, J. Yang and P. Zhu, Green Chem., 2019, 21, 3286 DOI: 10.1039/C8GC04066D

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements